Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
Xiufeng Liu,
Yinying Lu,
Weiping Zhou,
Tao Peng,
Jie Zhou,
Huaqiang Bi,
Feng Xia,
Xiaoping Chen
Affiliations
Xiufeng Liu
Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China
Yinying Lu
Comprehensive Liver Cancer Center, 5th Medical Center of PLA General Hospital, Beijing, China
Weiping Zhou
Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
Tao Peng
Hepatobiliary Surgery Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
Jie Zhou
Division of Hepatobiliopancreatic Surgery and Liver Transplantation, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China
Huaqiang Bi
Department of Hepatobiliary Surgery, The First Hospital Affiliated to Army Medical University, Chongqing, China
Feng Xia
Department of Hepatobiliary Surgery, The First Hospital Affiliated to Army Medical University, Chongqing, China
Xiaoping Chen
Department of Hepatobiliary Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary: To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the “Delphi” consensus formation method, and finally revised and completed the “Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)” on the basis of the 2021 edition. Key Messages: This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.
